within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK11_FormoterolAndFluticasone;

model FormoterolAndFluticasone
  extends Pharmacolibrary.Drugs.ATC.R.R03AK11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03AK11</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Formoterol and fluticasone is a fixed-dose combination medication consisting of formoterol, a long-acting beta2-adrenergic agonist (LABA), and fluticasone propionate, an inhaled corticosteroid (ICS), used in the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is approved in several regions as a combination inhaler for regular use in adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Estimates for healthy adult population after inhalation as published pharmacokinetic studies for the combination under ATC R03AK11 are lacking; values are approximated based on literature of each individual component when given as an inhaled combination.</p><h4>References</h4><ol><li><p>Dissanayake, S, et al., &amp; Dalvi, P (2023). Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy Volunteers. <i>Journal of aerosol medicine and pulmonary drug delivery</i> 36(2) 65–75. DOI:<a href=&quot;https://doi.org/10.1089/jamp.2022.0064&quot;>10.1089/jamp.2022.0064</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36796001/&quot;>https://pubmed.ncbi.nlm.nih.gov/36796001</a></p></li><li><p>McKeage, K (2013). Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. <i>Drugs</i> 73(2) 195–206. DOI:<a href=&quot;https://doi.org/10.1007/s40265-013-0016-4&quot;>10.1007/s40265-013-0016-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23397367/&quot;>https://pubmed.ncbi.nlm.nih.gov/23397367</a></p></li><li><p>Usmani, O, et al., &amp; Price, D (2019). An innovative corticosteroid/long-acting β. <i>Expert opinion on drug delivery</i> 16(12) 1367–1380. DOI:<a href=&quot;https://doi.org/10.1080/17425247.2019.1689957&quot;>10.1080/17425247.2019.1689957</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31752560/&quot;>https://pubmed.ncbi.nlm.nih.gov/31752560</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end FormoterolAndFluticasone;
